Illumina Inc. (ILMN): Today's Featured Drugs Loser

Illumina (ILMN) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.1%. By the end of trading, Illumina fell $1.41 (-3.4%) to $40.50 on light volume. Throughout the day, 1.8 million shares of Illumina exchanged hands as compared to its average daily volume of 2.9 million shares. The stock ranged in price between $40-$42.40 after having opened the day at $42.09 as compared to the previous trading day's close of $41.91. Other company's within the Drugs industry that declined today were: Prima Biomed Ltd. ADR (PBMD), down 15.8%, Tengion (TNGN), down 14.7%, Marshall Edwards (MSHL), down 13.1%, and Dendreon (DNDN), down 12.6%.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $5.27 billion and is part of the health care sector. The company has a P/E ratio of 65.2, above the average drugs industry P/E ratio of 64.3 and above the S&P 500 P/E ratio of 17.7. Shares are up 37.5% year to date as of the close of trading on Friday. Currently there are eight analysts that rate Illumina a buy, one analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Illumina as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and premium valuation.

• You can view the full Illumina Ratings Report.

On the positive front, Cleveland BioLabs (CBLI), up 63%, Zalicus (ZLCS), up 19.8%, Biosante Pharmaceuticals (BPAX), up 18.2%, and Auxilium Pharmaceuticals (AUXL), up 16.2%, were all gainers within the drugs industry with Bristol-Myers Squibb Company (BMY) being today's featured drugs industry winner.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

For more information on Illumina Inc. click any of the following:

• Illumina Inc. Stock Price

• Illumina Inc. Analyst Ratings

• Illumina Inc. Key Stats & Profile

• Illumina Inc. Earnings

• Illumina Inc. Ratio Comparison

• Illumina Inc. Growth Rates

• Illumina Inc. Balance Sheet

• Illumina Inc. Cash Flow

• Illumina Inc. Income Statement